ISGIDAR June 15th, 2024 International Study Group Investigating Drugs as Reinforcers Square Dorchester, 2nd Floor

	944410 20101100101, 2114 1 1001
7:45 – 8:30	Coffee and Registration
8:30 - 8:35	Opening Remarks
8:35 – 9:00	Richard A. Meisch, Colin N. Haile, and Therese A. Kosten Drugs as reinforcers. Misconceptions and methodological errors
9:00 – 9:25	Bill Fantegrossi , Brenda Gannon, Hannah Shaw, Kayla Wolf, Marina Avram, and Jeff Moran Synthetic fentanyl analogs as oral reinforcers in mice: A matter of taste
9:25 – 9:50	Cesar Ramon Romero Leguizamon, and Morgane Thomsen Do I feel comfortable attached to a fiber photometry patch cord?
	ISGIDAR Travel Award Recipient (Sponsored by Suzette Evans and Richard Foltin)
9:50 – 10:10	Coffee Break
10:10 – 10:35	Hannah N. Carlson , Samantha P. Armas, Jacob D. Camp, and Mark A. Smith <i>The positive reinforcing effects of cocaine and opposite-sex social contact</i>
	ISGIDAR Travel Award Recipient (Sponsored by Suzette Evans and Richard Foltin)
10:35 – 11:00	Emily M. Jutkiewicz , Ashleigh Matthews, Aaron Ajlen, Lucy Joying, Kenner C. Rice (Re)Evaluating the reinforcing effects of the delta opioid receptor agonist SNC80 in rodents
11:00 – 12:00	Wendy J. Lynch Shifts in the role of positive versus negative reinforcement in addiction President's Invited Lecture
12:00 – 1:00	Lunch
1:00 – 1:25	Matthew L. Banks , and Madison M. Marcus Effects of independent vs. dependent schedules on fentanyl vs. shock avoidance/escape choice in rats
1:25 – 1:50	Lindsey K. Galbo-Thomma, Carly Baehr, Marco Pravetoni, and Charles P. France A monoclonal antibody selectively attenuates fentanyl and carfentanil self-administration in rhesus monkeys
	William Woolverton Travel Award Recipient (Historically sponsored by Woolverton trainees; this year: Karen Anderson, Mike Nader, Sally Huskinson)
1:50 – 2:15	Emma Childs A comparison of two alcohol self-administration paradigms in moderate-heavy drinkers
2:15 – 2:35	Afternoon Break
2:35 – 3:00	Sandra D. Comer, Shanna Babalonis, Jermaine D. Jones, Paul A. Nuzzo, and Sharon L. Walsh A randomized, double-blind, placebo- and active-controlled, crossover study to evaluate the abuse potential of oxymorphone compared to other mu opioid agonists in physically dependent opioid users with moderate-to-severe opioid use disorder (FDA BAA-17-000123)
3:00 – 4:00	Panel, Abuse potential assessment of novel substances with putatively low abuse potential Chair and co-moderator: Jack E. Henningfield Discussant and co-moderator: Sandra D. Comer Panelists: Justin C. Strickland, James K. Rowlett, and Ziva D. Cooper
4:00 - 4:30	Business Meeting